Patent application number | Description | Published |
20080206321 | Oral drug delivery system - Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds. | 08-28-2008 |
20080260811 | Transdermal delivery systems - Transdermal delivery systems for administering sufentanil through the skin are provided. The systems contain a sufficient amount of sufentanil to induce and maintain a constant state of analgesia when applied to a subject. The systems are characterized as having one or more features including a high degree of dosage form rate control over flux of sufentanil from the system, a high net flux of sufentanil from the system through the skin, lack of a permeation enhancer, an adhesive member demonstrating superior shear time, a low coefficient of variation in the net flux of sufentanil from the system, a high delivery efficiency, and a substantially constant steady state net flux of sufentanil from the system. Methods of using the transdermal delivery systems to administer a sufficient amount of sufentanil to induce and maintain analgesia for extended periods when applied to a subject are also provided. | 10-23-2008 |
20090023689 | Oral drug delivery system - Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds. | 01-22-2009 |
20090023690 | Oral drug delivery system - Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds. | 01-22-2009 |
20090123518 | Biodegradable implants with controlled bulk density - Disclosed solid water permeable implants that include a water permeable polymer and an osmotically active drug formulation that comprises a drug; wherein the solid water permeable implant has a ratio R of bulk density of the solid water permeable implant to osmotic pressure of the drug formulation wherein R is greater than about 0.244 grams/milliliter-atm. Also disclosed are methods of making and using such solid water permeable implants. | 05-14-2009 |
20090298862 | Methods useful for the treatment of pain, arthritic conditions or inflammation associated with a chronic condition - Methods, including those for administering novel pharmaceutical compositions, dosage forms containing an opioid active pharmaceutical ingredient, are useful for treating pain, arthritic conditions and/or inflammation associated with a chronic condition, including pain from arthritis and inflammation. | 12-03-2009 |
20120135072 | Oral Drug Delivery System - Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds. | 05-31-2012 |
20120135073 | Oral Drug Delivery System - Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds. | 05-31-2012 |
20120225033 | Biodegradable Drug Delivery Composition - The present disclosure provides a biodegradable drug delivery composition including a vehicle and an insoluble component comprising beneficial agent dispersed in the vehicle. Typically, the composition is not an emulsion, but has a low viscosity and further provides for minimized initial burst and sustained release of the beneficial agent over time. Also provided, are kits including the biodegradable drug delivery composition or components thereof, as well as methods of making and using the biodegradable drug delivery composition. | 09-06-2012 |
20130259907 | Biodegradable Drug Delivery Composition - The present disclosure provides a biodegradable drug delivery composition including a vehicle and an insoluble component comprising beneficial agent dispersed in the vehicle. Typically, the composition is not an emulsion, but has a low viscosity and further provides for minimized initial burst and sustained release of the beneficial agent over time. Also provided, are kits including the biodegradable drug delivery composition or components thereof, as well as methods of making and using the biodegradable drug delivery composition. | 10-03-2013 |
20130273139 | TRANSDERMAL DELIVERY SYSTEMS - Disclosed are bupivacaine transdermal delivery systems, and related methods. | 10-17-2013 |
20130281480 | Oral Drug Delivery System - Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds. | 10-24-2013 |
20130287845 | Oral Drug Delivery System - Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds. | 10-31-2013 |
20130295168 | Oral Drug Delivery System - Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds. | 11-07-2013 |
20130317049 | Methods Useful for the Treatment of Pain, Arthritic Conditions or Inflammation Associated with a Chronic Condition - Methods, including those for administering novel pharmaceutical compositions, dosage forms containing an opioid active pharmaceutical ingredient, are useful for treating pain, arthritic conditions and/or inflammation associated with a chronic condition, including pain from arthritis and inflammation. | 11-28-2013 |
20130317456 | Transdermal Delivery Systems - Disclosed are bupivacaine transdermal delivery systems, and related methods. | 11-28-2013 |
20140080870 | Transdermal Delivery Systems - Transdermal delivery systems for administering sufentanil through the skin are provided. The systems contain a sufficient amount of sufentanil to induce and maintain a constant state of analgesia when applied to a subject. The systems are characterized as having one or more features including a high degree of dosage form rate control over flux of sufentanil from the system, a high net flux of sufentanil from the system through the skin, lack of a permeation enhancer, an adhesive member demonstrating superior shear time, a low coefficient of variation in the net flux of sufentanil from the system, a high delivery efficiency, and a substantially constant steady state net flux of sufentanil from the system. Methods of using the transdermal delivery systems to administer a sufficient amount of sufentanil to induce and maintain analgesia for extended periods when applied to a subject are also provided. | 03-20-2014 |
20140193365 | Biodegradable Drug Delivery Composition - The present disclosure provides a biodegradable drug delivery composition including a vehicle and an insoluble component comprising beneficial agent dispersed in the vehicle. Typically, the composition is not an emulsion, but has a low viscosity and further provides for minimized initial burst and sustained release of the beneficial agent over time. Also provided, are kits including the biodegradable drug delivery composition or components thereof, as well as methods of making and using the biodegradable drug delivery composition. | 07-10-2014 |
20140275147 | Compositions with a Rheological Modifier to Reduce Dissolution Variability - The present disclosure provides compositions (e.g., extended release compositions) which exhibit a desirable pharmacokinetic profile of an active agent while providing reduced dissolution sample variability, e.g., in the form of reduced inter-capsule variability and/or a reduction in storage-time dependent change in mean release of the active agent from the composition. Related methods of making and administering the disclosed compositions and formulations are also provided. | 09-18-2014 |
20140294977 | Radiation-Sterilized Biodegradable Drug Delivery Composition - The present disclosure is directed to a method of making a composition by combining a vehicle, e.g., a single phase vehicle, and an insoluble component comprising a beneficial agent, and sterilizing the composition using ionizing radiation prior to use, wherein the beneficial agent is stable following exposure to a sterilizing dose of ionizing radiation. Related compositions and methods are provided. | 10-02-2014 |